Gold tier: mechanically validated evidence, with its primary source.
64 evidence items · page 3 / 3
57.1 %Cumulative proportion of HBeAg seroclearance was 57.1% in patients with baseline pcG1896A mutation and 54.3% in those without, among antiretroviral-naïve HIV-HBV co-infected patients from Côte d'Ivoire.
Côte d'Ivoirehépatite Bpublished 2018Journal of viral hepatitiseurope_pmcdocument of 7 observationsDOI 10.1111/jvh.12914
25.7 %Among 879 participants in the Temprano randomized control trial, 226 (25.7%) had resolved hepatitis B virus infection (HBsAb-positive/HBcAb-positive).
Côte d'Ivoirehépatite Bobserved 2008 and 2015published 2021Journal of viral hepatitiseurope_pmcdocument of 5 observations
1.9 per_100_person-yearsParticipants with HBsAg and high HBV DNA had an all-cause mortality incidence of 1.9 per 100 person-years.
Côte d'Ivoirehépatite B · VIH/sidaobserved 2008 and 2015published 2021Journal of viral hepatitiseurope_pmcdocument of 5 observations
7.3 per_100_person-yearsHBsAg seroconversion incidence among regular blood donors in Abidjan decreased from 7.3 per 100 person-years in 1992–1994 to 0.2 per 100 person-years in 2010–2012.
Côte d'Ivoirehépatite Bobserved 1992–1994published 2018Open forum infectious diseaseseurope_pmcdocument of 12 observations
0.9 sensitivityqHBsAg levels ≤ 10 IU/mL at month 12 had sensitivity of 0.90 and specificity of 1.00 for predicting HBsAg seroclearance.
Côte d'Ivoirehépatite Bobserved month 12published 2016Journal of gastroenterology and hepatologyeurope_pmcdocument of 11 observationsDOI 10.1111/jgh.13156
12.9 per_100_person_yearsThe incidence rate of bacterial infections was 12.9 per 100 person-years among HIV-HBV co-infected patients with HBV-replication > 10,000 copies/mL.
Côte d'Ivoirehépatite B · VIH/sidapublished 2017The American journal of tropical medicine and hygieneeurope_pmcdocument of 7 observationsDOI 10.4269/ajtmh.16-1016
2.3 per_100_person-yearsHBsAg seroconversion incidence among regular female blood donors in Abidjan decreased from 2.3 per 100 person-years in 1992–1994 to 0.2 per 100 person-years in 2010–2012.
Côte d'Ivoirehépatite Bobserved 1992–1994published 2018Open forum infectious diseaseseurope_pmcdocument of 12 observations
10.3 %Among 632 participants from Côte d'Ivoire in a randomized-control trial, 65 (10.3%) were hepatitis B surface antigen (HBsAg)-positive.
Côte d'Ivoirehépatite Bpublished 2017The American journal of tropical medicine and hygieneeurope_pmcdocument of 7 observationsDOI 10.4269/ajtmh.16-1016
43 patientsAmong 43 HBeAg-negative HIV/HBV co-infected patients not indicated for ART in Côte d'Ivoire, 17 (40%) consistently had 'infection', 5 (12%) consistently had 'hepatitis', and 21 (48%) fluctuated between phases during follow-up.
Côte d'Ivoirehépatite B · VIH/sidapublished 2019Transactions of the Royal Society of Tropical Medicine and Hygieneeurope_pmcdocument of 4 observations
11.7 %HBsAg positivity prevalence among first-time male blood donors in Abidjan was 11.7% in 1992–1994 and 12.5% in 2010–2012.
Côte d'Ivoirehépatite Bobserved 1992–1994published 2018Open forum infectious diseaseseurope_pmcdocument of 12 observations
3.82 adjusted_IRRHBsAg-positive individuals with HBV-DNA ≥2000 IU/mL had an adjusted incidence rate ratio for mortality of 3.82 (95% CI = 1.11–9.70) at CD4+ counts ≤350/mm³ compared to HBsAg-negative individuals.
Côte d'Ivoirehépatite B · VIH/sidapublished 2021Antiviral therapyeurope_pmcdocument of 4 observations
5.2 log10_copies_per_mlMedian HBV DNA level was 5.2 log(10) copies/ml for patients with chronic hepatitis B.
Côte d'Ivoirehépatite Bpublished 2010Antiviral therapyeurope_pmcdocument of 7 observations
0.8 sensitivityDetectable HBV-DNA at month 12 had sensitivity of 0.80 and specificity of 0.40 for predicting HBsAg seroclearance.
Côte d'Ivoirehépatite Bobserved month 12published 2016Journal of gastroenterology and hepatologyeurope_pmcdocument of 11 observationsDOI 10.1111/jgh.13156
22.2 %Among 36 HBsAg-positive patients with available blood samples, 8 (22.2%) had detectable HBV DNA.
Côte d'Ivoirehépatite Bobserved 2012published 2017BMC infectious diseaseseurope_pmcdocument of 7 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.